Patients with newly diagnosed multiple myeloma (NDMM) exhibit varying outcomes, with around 60% classified as intermediate-risk under the Revised International Staging System (R-ISS). Chromosome 1q gain/amplification (1q+) has recently been...

The Stratification for Myeloma and Risk-Adapted Therapy (mSMART) guidelines, developed to provide clear and effective treatment protocols for multiple myeloma, were introduced due to the lack of structured treatment approaches...

Patients with monoclonal gammopathy of undetermined significance or smoldering multiple myeloma are at a higher risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia compared to the general population....

In patients with multiple myeloma, infection is the primary cause of morbidity and mortality, influenced by a combination of the disease itself, treatments, and individual patient factors. The risk of...

A study with 1996 patients with smoldering multiple myeloma (SMM) established a risk stratification system to predict progression to multiple myeloma (MM) within two years. Three key factors – serum...

Researchers analyzed the critical role osteocytes play in the development of myeloma bone disease (MBD), a major complication in multiple myeloma (MM). Osteocytes contribute to increased osteoclast activity, reduced osteoblast...